Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549
-------------	------------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL										
	OMB Number: 3235-0287										
	Estimated average	burden									
- 1	hours nor response	. 0 =									

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Dunlop A. Sinclair					2. Issuer Name and Ticker or Trading Symbol Apellis Pharmaceuticals, Inc. [APLS]											ck all app	tor			10% Owner	
(Last) (First) (Middle) C/O APELLIS PHARMACEUTICALS, INC. 100 FIFTH AVENUE, 3RD FLOOR					3. Date of Earliest Transaction (Month/Day/Year) 03/01/2023											Office below	er (give			ther (specify elow)	
100 FIFTH AVENUE, 3RD FLOOR				_ 4	4. If Amendment, Date of Original Filed (Month/Day/Year)										6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street) WALTHAM MA 02451															X Form filed by One Reporting Person Form filed by More than One Reporting Person						- 1
(City)	(Sta	ate) (Z	Zip)																		
		Table	I - Non-Deriv	/ativ	/e S	Secui	rities	Ac	quir	ed, D	is	posed o	f, or E	Benefic	iall	y Own	ed				
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Y				Execution Date,		,	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 ar 5)				Beneficially Owned Following			6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership			
								Code	v	Amount		(A) or (D)	Price	Ti	eported ransaction nstr. 3 and			(Instr. 4)			
Common Stock 03/01/2)23	23				S ⁽¹⁾			500	D	\$65.33		131,797		D				
Common Stock																240,679		I		Indirect Owner (Epidarex) ⁽²⁾	
Common Stock														31,855		I		Indirect Owner (Masa) ⁽³⁾			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year	4. Transaction Code (Instr. 8) S Overland Acquire (A) or Dispose of (D) (Instr. 3, and 5)				ative rities ired osed	Expiration (Month/Dates ed				Amou Secu Unde Deriv	rlying ative rity (Instr.			9. Num derivat Securi Benefi Owned Follow Report Transa (Instr.	tive ties cially I ing ied action(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Co	Code V (A) (D			(D)	Date) Exercisabl		le	or Numb Expiration of		or Number							

Explanation of Responses:

- 1. The sale reported on this Form 4 was effected by pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 23, 2022.
- 2. The securities are held by Epidarex and the reporting person, a general partner of Epidarex, may be deemed to have voting and dispositive power over the shares held by Epidarex. The reporting person disclaims beneficial ownership over the shares held by Epidarex except to the extent of his pecuniary interest therein.
- 3. The securities are held by MASA and the reporting person, a managing partner of MASA, may be deemed to have voting and dispositive power over the shares held by MASA. The reporting person disclaims beneficial ownership over the shares held by MASA except to the extent of his pecuniary interest therein.

/s/ David Watson, attorney-infact for Sinclair Dunlop

03/02/2023

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.